Posted from: Friday, July 07, 2017 - 02:38 PM - Present

First Generic Launched for Pataday

June 9, 2017 – Teva Pharmaceutical Industries has launched the first A-rated generic to Alcon Laboratories’ Pataday® (olopatadine ophthalmic solution 0.2%). Olopatadine is a mast cell stabilizer that helps to relieve itchy eyes caused by allergic conjunctivitis. Recommended dosing is one drop in the affected eye(s) each day. Olopatadine is dispensed in 5mL plastic dropper bottles that contain 2.5mL of solution. QuintilesIMS estimates that U.S. sales for Pataday accounted for $303 million over a one-year period as of March 31, 2017. Teva will have 180 days of generic exclusivity.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Saturday, September 23, 2017 - 06:45 AM.